business
Jump to
16 Results Found
  • Hope to launch 12-15 new products in next one year: Strides Shasun Feb 23, 2018 02:46 PM IST

    Hope to launch 12-15 new products in next one year: Strides Shasun

    An IIFL report quotes the management of Strides Shasun as saying that pharmaceutical benefits scheme price cuts have bottomed out. In an interview to CNBC-TV18, Shashank Sinha, MD of the company spoke about the same and gave his outlook for the future.

  • Book profits on rallies as Nifty is witnessing a ‘Bearish Butterfly’ on the charts Dec 24, 2017 10:07 AM IST

    Book profits on rallies as Nifty is witnessing a ‘Bearish Butterfly’ on the charts

    Jay Purohit, Technical & Derivatives Analyst at Centrum Broking Limited, says short-term traders are advised to book some profit at current levels.

  • Will be vertically integrated formulation company: Strides Shasun Sep 25, 2017 04:07 PM IST

    Will be vertically integrated formulation company: Strides Shasun

    In an interview to CNBC-TV18, Shashank Sinha, MD & GROUP CEO of Strides Shasun spoke about the latest happenings in his company and sector.

  • Remain bullish about performance overall in FY18: Strides Shasun Jul 17, 2017 12:33 PM IST

    Remain bullish about performance overall in FY18: Strides Shasun

    Strides Shasun may receive approval for Lovaza generic, which has a market size of around USD 750-800 million in the United Sates and could make upto USD 200 million annually for the company. There has been a lot of buzz around pending application for Omega 3 which is the generic version of Lovaza, Shashank Sinha, MD & Group CEO of Strides Shasun told CNBC-TV18.

  • Sequent Scientific gets CCI approval for Scheme of Arrangement Jul 03, 2017 02:26 PM IST

    Sequent Scientific gets CCI approval for Scheme of Arrangement

    Competition Commission of India (CCI) approves Scheme of Arrangement between Strides Shasun, Sequent Scientific and Solara Active Pharma Sciences. In an interview to CNBC-TV18, Manish Gupta, CEO of Sequent Scientific spoke about the same.

  • Regulatory claims on Agila settled, says Strides Shasun Nov 03, 2016 11:42 AM IST

    Regulatory claims on Agila settled, says Strides Shasun

    There was some regulatory overhangs post Strides-Mylan Agila transaction, says Arun Kumar, Executive VC & MD of Strides Shasun.

  • Data integrity issues hamper relations with regulators: Strides Sep 09, 2016 10:30 PM IST

    Data integrity issues hamper relations with regulators: Strides

    In an interview to CNBC-TV18, Arun Kumar, Founder & MD of Strides Shasun says that the pharma industry lacks trust now as more and more issues with regulators come to light.

  • Hope to complete merger formalities by October end: Shasun Aug 11, 2015 12:33 PM IST

    Hope to complete merger formalities by October end: Shasun

    Abhaya Kumar, MD at Shasun Pharmaceuticals said the company's merger with Strides will be completed as soon as court approvals of the latter are in place. He is sure the merged entity will be effective from April 1 2015 itself.

  • Strides Arcolab to buy Aspen's generic biz in Australia May 21, 2015 01:02 PM IST

    Strides Arcolab to buy Aspen's generic biz in Australia

    The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.

  • Special dividend of Rs 500/share to cost us $525mn: Strides Dec 10, 2013 02:01 PM IST

    Special dividend of Rs 500/share to cost us $525mn: Strides

    Strides Arcolab has a fairly strong organic growth strategy in place at the moment, says Group CEO & VC Arun Kumar.

  • Ailing pharma sector needs uniform drug standards: Ranbaxy Sep 05, 2013 01:32 PM IST

    Ailing pharma sector needs uniform drug standards: Ranbaxy

    Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.

  • Strides Arcolab arm in JV with Pfenex for biosimilar drugs Apr 17, 2013 01:28 PM IST

    Strides Arcolab arm in JV with Pfenex for biosimilar drugs

    Strides Arcolab‘s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market

  • Sale proceeds to help cut debt, repay FCCB: Strides Arcolab Jan 24, 2012 04:00 PM IST

    Sale proceeds to help cut debt, repay FCCB: Strides Arcolab

    Strides Arcolab aims to use the funds received through the sale of its Southeast Asian and Australian units to repay foreign currency convertible bondholders and reduce the debt, says group chief executive and vice chairman Arun Kumar.

  • Strides Arcolab eyes 30-35% growth in current year Jul 01, 2011 12:53 PM IST

    Strides Arcolab eyes 30-35% growth in current year

    In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.

  • Strides, Pfizer to deal post US FDA nod on Oncology unit May 02, 2011 12:58 PM IST

    Strides, Pfizer to deal post US FDA nod on Oncology unit

    Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.

  • Strides Arcolab expects more approvals from US FDA soon Mar 01, 2011 04:41 PM IST

    Strides Arcolab expects more approvals from US FDA soon

    In an interview with CNBC-TV18, Arun Kumar, Group CEO and Vice Chairman, Strides Arcolab spoke on the development and the way forward for the company.

Sections